The results of the effectiveness of pharmaceutical treatment of chronic gastritis with erosions associated with Helicobacter pyloriwith azithromycin and amoxicillin in the elderly

Digestive diseases, chronic gastritis with erosions being one of them, are common in elderly patients. Helicobacter pylori infection is one of the etiopathogenetic factors of chronic gastritis. Eradication therapy is currently considered one of the main treatments and prophylaxis of H. pylori infection. However, the increase in the duration of eradication therapy leads to an increase in the frequency of side effects, especially in the gastrointestinal tract, as well as the risk of cardiotoxicity which results in a decrease in the patient's compliance with therapy.

The aim of the study was to evaluate the effectiveness of H. pylori eradication in the treatment of chronic gastritis with erosions using azithromycin and amoxicillin.

Material and methods. A clinical and endoscopic examination of 134 patients with chronic gastritis with erosions associated with H. pylori was carried out. Depending on the treatment regimen, all patients were divided into 2 groups. The first group consisted of patients who received azithromycin for 5 days and amoxicillin for 10 days, omeprazole 2 times a day for 14 days, then once daily for 4 weeks, De-Nol for 28 days. In the second group, patients received clarithromycin and amoxicillin for 14 days, omeprazole 2 times a day for 14 days, then once daily for 4 weeks, De-Nol for 28 days. Control studies were conducted 6 weeks after the end of drug administration.

Results. Abdominal and sternal pain, dysphagia, nausea, heartburn, vomiting, bloating, stool disorders — diarrhea or constipation — were the predominant complaints in the elderly patients. Assessment of the local effectiveness of the applied eradication regimens allows the select of the most effective and safe therapyregimens.

Conclusion. Given the short course of administration of azithromycin (5 days) and  (10 days), these drugs can be used in patients with low adherence to treatment, as well as for prevention of complications caused by antibiotics in elderly patients who are constantly taking medications for other diseases.

1. Vernigorodskii S.V. Analiz strukturnykh izmenenii slizistoi obolochki zheludka i ikh osobennosti pri khronicheskom gastrite. Nauka Molodykh. 2014; 1: 37–43. (in Russian)]

2. Minushkin O.N., Zverkov I.V. Khronicheskii gastrit. Lechashchii Vrach. 2003; 5: 24–31. (in Russian)]

3. Лазебник Л.Б. Полиморбидность у пожилых. Сердце. 2007; 7: 25–27. [Lazebnik L.B. Polimorbidnost' u pozhilykh. Serdtse. 2007; 7: 25–27. (in Russian)]

4. Lazebnik L.B. Polimorbidnaya bronkholegochnaya i gastroenterologicheskaya patologiya u pozhilykh. Tezisy dokladov mezhvuzovskoi terapevticheskoi konferentsii. Moscow: 2008. [In Russian]

5. Gileva V.V. Mekhanizmy, formirovaniya polimorbidnosti u zhenshchin pozhilogo vozrasta: avtoref. diss. kand. med. nauk. Sankt.-Peterburg: Institut bioregulyatsii i gerontologii SZO RAMN; 2009. (in Russian])

6. Denisova T.P., Tyul'tyaeva L.A. Geriatricheskaya gastroenterologiya: Izbrannye lektsii. Moscow: OOO «Meditsinskoe informatsionnoe agentstvo», 2011. (in Russian)]

7. Grigor'ev P.Ya. Helicobacter pylori: gastrit, duodenit, (gastroduodenit), yazvennaya bolezn'. Praktikuyushchii Vrach. 1999; 16: 2–6. (in Russian)]

8. Yakovenko E.P., Vasil'ev N.N., Yakovenko A.V., Agafonova N.A. i dr. Prakticheskie podkhody k lecheniyu khronicheskogo gastrita, assotsiirovannogo s Helicobacter pylori. Eksperimental'naya i Klinicheskaya Gastroenterologiya. 2019; 165(5): 154–160. doi: https://doi.org/10.31146/1682-8658-ecg-165-5-154-160. (in Russian)]

9. O’Connor A., Fisсhbaсh W., Gisbert J.P., O’Morain C. Treatment of Helicobacter pylori infection. Hеliсobасtеr. 2016; 21 (1): 55–61. doi: 10.1111/hel.12342.

10. Tellier G., Niederman M.S., Nusrat R. et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate communityacquired pneumonia. J Antimicrob Chemother. 2004; 54: 515–523. doi: 10.1093/jac/dkh356.

11. Dolgalev I.V., Kareva E.N., Lyalyukova E.A., Pavlova N.V. Khronicheskii gastrit: ot gistologicheskogo protokola do obosnovaniya etiopatogeneticheskoi terapii. Lechashchii Vrach. 2021; № 2 (24): 30–34. [In Russian] doi.org/10.26295/OS.2021.76.84.006

12. Aruin L.I., Kapuller L.L., Isakov V.A. Morfologicheskaya diagnostika boleznei zheludka i kishechnika. Moscow: «Triada-X», 1998. [In Russian]

13. Malfertheiner P., Megraud F., Rokkas T., et al. Management of Helicobacter pylori infection: the Maastricht VI. Florence consensus report. Gut. 2022; 71: 1724–1762. doi: 10.1136/gutjnl-2022-327745.

14. Maev I.V., V'yuchnova E.G., Petrova E.G. Pobochnye deistviya sovremennoi antikhelikobakternoi terapii. Klinicheskaya Meditsina. 2002; 6: 7–12. (in Russian)]

15. Postnikov S.S., Gratsianskaya A.N., Kostyleva M.N., Sobakinskaya T.V. Redkie nezhelatel'nye effekty klaritromitsina. Klinicheskaya Farmakologiya. 2008; 2: 20–22. (in Russian)]

16. Sinopal'nikov A.I. Bezopasnost' makrolidnykh antibiotikov: kriticheskii analiz. Klinicheskaya Meditsina. 2012; 3: 23–30. (in Russian)]

17. Winkel P., Hilden J., Hansen J.F., Kastrup J. et al. CLARICOR trial group. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10 years in the CLARICOR randomised, blinded clinical trial. Int J Cardiol. 2015; 182: 459–465. doi: 10.1016/j.ijcard.2015.01.020.

18. Liou, J.M., Fang Y.J., Chen C.C. et.al. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2016; 388 (10058): 2355–2365. doi: 10.1016/S0140-6736(16)31409-X.

19. Pavlenko V.I., Goncharova O.M., Soluyanova I.P. Kislotozavisimye i assotsiirovannye s Helicobacter pylori zabolevaniya v praktike uchastkovogo vracha-terapevta: uchebnoe posobie. Blagoveshchensk: Amurskaya GMA. 2021. (in Russian)]

20. Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents. 2001; 18 (Suppl 1): S71–S76. doi: 10.1016/s09248579(01)00397-1.

21. Kuzman I., Dakovic-Rode O., Oremus M. et al. Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, openlabel study. J Chemother. 2005; 17: 636–642. doi: 10.1179/joc.2005.17.6.636.

22. Paris R., Confalonieri M., Dal Negro R et al. Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of communityacquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days. J Chemother. 2008; 20: 77–86. doi: 10.1179/joc.2008.20.1.77.

23. Yanagihara K., Izumikawa K., Higa E. et al. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection. Intern Med. 2009; 48: 527–535. doi: 10.2169/internalmedicine.48.1482.

24. Bonvehi P., Weber K., Busman T. et al. Comparison of clarithromycin and amoxicillin/clavulanic acid for community-acquired pneumonia in an era of drug-resistant Streptococcus pneumonia. Clin. Drug Invest. 2003; № 23: 491–501. DOI: 10.2165/00044011-200323080-00001

25. Lee P.I., Wu M.H., Huang L.M. et al. An open, randomized, comparative study of clarithromycin and erythromycin in the treatment of children with community-acquired pneumonia. J Microbiol Immunol Infect. 2008; 41: 54–61.

26. Snyman J.R., Schoeman H.S., Grobusch M.P. et al. Generic versus nongeneric formulation of extended-release clarithromycin in patients with community-acquired respiratory tract infections: a prospective, randomized, comparative, investigator-blind, multicentre study. Clin Drug Invest. 2009; 29: 265–274. doi: 10.2165/00044011-200929040-00005.

27. Tellier G., Niederman M.S., Nusrat R. et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate communityacquired pneumonia. J Antimicrob Chemother. 2004; 54: 515–523. doi: 10.1093/jac/dkh356.

28. Christopher K., Hyatt P.A., Horkan C. et al. Clarithromycin use preceding fulminant hepatic failure. Am J Gastroenterol. 2002; 97: 489. doi: 10.1111/j.1572-0241.2002.05505.x.

29. de Abajo F.J., Montero D., Madurga M. et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004; 58: 71–80. doi: 10.1111/j.1365-2125.2004.02133.x.

30. Masia M., Gutierrez E., Jimeno A. et al. Fulminant hepatitis and fatal toxic epidermal necrolysis (Lyell disease) coincident with clarithromycin administration in an alcoholic patient receiving disulfi-ram therapy. Arch Intern Med. 2002; 162 (4): 474–476. doi: 10.1001/archinte.162.4.474.

31. Belousov Yu.B. Lekarstvennye porazheniya pecheni, assotsiiruemye s makrolidami. Ochevidna li svyaz'? Russkiy Meditsinsky Zhurnal. 2011; 19 (18): 3–7. (in Russian)]

32. Chang C.Y., Schiano T.D. Review article: drug hepatotoxicity. Aliment Pharmacol Ther. 2007; 25 (10): 1135–1151. doi: 10.1111/j.13652036.2007.03307.x.

33. Simko J., Csilek A., Karaszi J. et al. Proarrhythmic potential of antimicrobial agents. Infection. 2008; 36 (3): 194–206. doi: 10.1007/s15010-007-7211-8.

34. Ohtani H., Taninaka C., Hanada E. et al. Comparative pharmacodynamic analysis of QT interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin. Antimicrob Agents Chemother. 2000; 44 (10): 2630–2637. doi: 10.1128/AAC.44.10.2630-2637.2000.